AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03033095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept ® 50 mg
Description: The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
Study NCT03674853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wuling Capsule
Description: take Wuling Capsule in experiment group for 2 months
Study NCT03674853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oryzanol
Description: take oryzanol in active comparator group for 2 months
Study NCT01610011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine administration
Description: Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
Study NCT03313453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PuriCare (HEPA Air Cleaner)
Description: The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
Study NCT03313453 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mock device of PuriCare
Description: The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
Study NCT02309060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Video Intervention (sTVi)
Description: Narrative communication, video-based intervention for depressed primary care patients.
Study NCT04003220 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample
Description: The extra samples will be taken Blood sampling
Study NCT04003220 — intervention group
Intervention type: PROCEDURE
Intervention: Bone marrow sample
Description: This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
Study NCT00604864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti TNFa monoclonal antibody - Infliximab
Description: Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
Study NCT00604864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT03392025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed
Description: Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months
Study NCT03392025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the Mediterranean-like diet
Description: Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months
Study NCT03392025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
Study NCT00132613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Observation alone after pericardial drainage
Study NCT00132613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pericardial instillation of bleomycin after drainage
Study NCT04800809 — intervention group
Intervention type: OTHER
Intervention: This study does not entail offering any intervention; all data collected will be based on standard of care.
Description: This study does not entail offering any intervention; all data collected will be based on standard of care.
Study NCT00705523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: 1.0 mg BID for 12 weeks
Study NCT00705523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: BID 12 weeks
Study NCT04493190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapular control training
Description: Participants in this group will learn how to maintain normal scapular position at first. Then they will progress to moving arm with good scapular control with mirror. Afterward, participants will undergo movements protocol which give different directions of arm movements while keeping scapula in a good alignment. They will also receive scapular-focused exercises. The difficulty of the movement protocol will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
Study NCT04493190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General exercise
Description: Participants in this group will receive a general shoulder strengthening with theraband or dumbbell. Load will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
Study NCT00316134 — intervention group
Intervention type: PROCEDURE
Intervention: Procedure/Surgery
Description: Diagnostic and/or therapeutic procedure to remove pleural fluid.
Study NCT03149471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial dysfunction test
Description: The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
Study NCT01493648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
Study NCT01493648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (lactose 100 mg) for 3 months.
Study NCT02803047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation number - SR15-61-Z15-034).
Study NCT01504308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU treatment
Description: A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
Study NCT01504308 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
Study NCT02850211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
Study NCT02850211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
Study NCT02850211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
Study NCT02422251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile high congruency bearing (Columbus)
Description: Columbus high congruency bearing on a rotating platform tibia.
Study NCT02422251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed high congruency bearing (Columbus)
Description: Columbus high congruency bearing on a fixed platform tibia.
Study NCT02422251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed high congruency bearing (Columbus)
Description: Columbus deep dish bearing on a fixed platform tibia.
Study NCT02536703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: Lotus Valve System
Study NCT01562171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooked Lentils
Description: Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
Study NCT01562171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potato-Based Foods
Description: Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
Study NCT02934022 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Maraviroc
Description: 150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
Study NCT00567216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadolol
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Study NCT00160355 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic stem cell transplantation
Description: To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
Study NCT00160355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi CliniMACS selection system
Description: This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
Study NCT00160355 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, Melphalan, Thiotepa
Description: Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
Study NCT00730561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
Study NCT00695253 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Talent Endoluminal Spring Graft System
Description: Endovascular repair for patients with AAA who meet the inclusion criteria for the study
Study NCT02099903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter renal denervation
Description: Renal sympathetic denervation with an irrigated radiofrequency catheter.
Study NCT01690364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MEP monitoring with continuous infusion of vecuronium during general anesthesia
Description: MEP monitoring with continuous infusion of vecuronium during general anesthesia
Study NCT01690364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEP monitoring with continuous infusion of cisatracurium during general anesthesia
Description: MEP monitoring with continuous infusion of cisatracurium during general anesthesia
Study NCT00617032 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single Dose 1x10\^10 DNase resistant particles (DRP) / mL joint volume
Study NCT00617032 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single dose 1x10\^11 DNase resistant particles (DRP) / mL joint volume
Study NCT00617032 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: tgAAC94 placebo
Description: Single dose
Study NCT00802009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
Study NCT00802009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivicaine
Description: Standard anesthetic solution administered during routine brachial plexus nerve blockade.
Study NCT00802009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivicaine
Description: Standard anesthetic solution administered during routine brachial plexus nerve blockade.
Study NCT01071135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
Study NCT00759330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tape (Arm 1)
Description: Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
Study NCT00759330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Tape (Arm 2)
Description: Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
Study NCT00759330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tape (Arm 3)
Description: Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
Study NCT00759330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Tape (Arm 4)
Description: Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
Study NCT02115425 — intervention group
Intervention type: OTHER
Intervention: Body Measurements
Description: A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
Study NCT02115425 — intervention group
Intervention type: OTHER
Intervention: Whole Body DXA Scan
Description: This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
Study NCT02115425 — intervention group
Intervention type: OTHER
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
Study NCT02115425 — intervention group
Intervention type: OTHER
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
Study NCT02115425 — intervention group
Intervention type: OTHER
Intervention: add name here
Study NCT01050348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin calcium
Description: Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
Study NCT01050348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
Study NCT01135706 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This study does not include an intervention but is observational in nature.
Study NCT04430465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grain products high in wholegrains from oat and rye
Description: A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
Study NCT04430465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grain products low in wholegrains
Description: A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
Study NCT00842881 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Healingstone navel belt
Description: 6\~8hours/day for 3months
Study NCT01633814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Description: transdermal estradiol, delivery rate 100 µg day-1
Study NCT01633814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo patch.
Study NCT04251650 — intervention group
Intervention type: OTHER
Intervention: subgingival plaque sample
Description: for subgingival plaque sample, on three affected sites (PD>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.
Study NCT04251650 — intervention group
Intervention type: OTHER
Intervention: CGF sample
Description: each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites
Study NCT02844049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: surgical procedure
Study NCT01862133 — intervention group
Intervention type: OTHER
Intervention: Patient preferences
Description: Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
Study NCT01975454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
Study NCT01975454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
Study NCT01975454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal therapy
Description: TLBZT based herbal decoction administered orally twice a day
Study NCT01520896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: Oral 25 mg
Study NCT01520896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NKTR-118
Description: Oral 25 mg
Study NCT01520896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Oral 400 mg
Study NCT01210079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin;
Description: Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
Study NCT01210079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo titrated over 1 week with established dose taken daily for 5 weeks.
Study NCT02804178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-101
Description: 125-1000 mg twice per week